Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment

Clin Oncol (R Coll Radiol). 2021 Feb;33(2):92-97. doi: 10.1016/j.clon.2020.10.020. Epub 2020 Nov 12.


Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (177Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.

Trial registration: NCT03511664 NCT03872778.

Keywords: (177)Lu-DOTATATE; PRRT; individualised; neuroendocrine tumours; personalised; radionuclide therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Neuroendocrine Tumors* / radiotherapy
  • Precision Medicine*
  • Prospective Studies
  • Radioisotopes
  • Receptors, Peptide
  • Retrospective Studies


  • Radioisotopes
  • Receptors, Peptide

Associated data